Biotech Mid-Cap Momentum Leaders and Laggards…Update…gene editing

http://moneyrebound.com/comment-subscriptions?srp=1382 Update-1 Gene Editing stocks are hit hard by a STAT Report that edited cells may cause cancer. Here is a later summary from STAT. As of 2:45 PDT trading; CRSP down 12% at $60,  EDIT down 7.8% at $36.14. NTLA down 9.9% at $24.5. The report was published in Nature Medicine.

After the close biotech stocks were mixed with some notable winners:  BPMC, ECYT, IONS, SGEN.

========

http://castelloristorante.com/rioxuaw/vkzieur.php?uik=Moose-Eaten-Alive-by-Bear-wild-animals-Wild-Life-t-Wild Mid-Cap Biotechs: Performance Post ASCO

We will update our biotech mid-cap performance list on Tuesday but here are the momentum leaders near 52 week highs after ASCO news and updates.We will also update our mid-cap list at the six month mark.

ETFs: source FBT,QQQ,XBI

52 Week leaders

AGIO, ARRY, CRSP, FMI, FOLD, GWPH, LGND, LOXO, NBIX, SGEN, SRPT

52 Week laggards

ACAD, ANAB, CLVS, EXEL, INCY, IONS, TSRO

 

 

, , , ,

No comments yet.

Leave a Reply